Delivery Order SPE2DX22D0010-SPE2D825FEX02
Award Date
4/11/25
Potential Completion Date
4/14/25
Potential Value
$3.6K
Federal Agency
Medical Supply Chain
Awardee
Amerisourcebergen Drug Corp
Ultimate Awardee
Not listed
NAICS Category
325411 - Medicinal and Botanical Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,974.70 firm fixed-price contract is for the supply of Quillivant XR 25 mg/5 ml suspension, a medication used to treat attention-deficit/hyperactivity disorder (ADHD). The contract is not set-aside and has an ultimate completion date of May 1, 2025. AmerisourceBergen Drug Corp holds a larger $999,999,999.00 Indefinite...
This is a $3,102.86 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract covers the supply of Quillivant XR 25 mg/5 ml suspension, a medication used for the treatment of attention-deficit/hyperactivity disorder (ADHD). The contract has an ultimate completion date of January 13, 2025. AmerisourceBergen holds a $999,999,999 Indefinite Delivery...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,648.54 firm fixed price contract is for the supply of Quillivant XR 25 mg/5 mL oral suspension, a medication used to treat attention-deficit/hyperactivity disorder (ADHD). The contract has an ultimate completion date of January 27, 2025 and is not designated as a set-aside. AmerisourceBergen holds a $999,999,999...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $5,131.14, is for the supply of Quillivant XR oral suspension, a medication used for the treatment of attention-deficit/hyperactivity disorder (ADHD). The contract has a firm fixed-price pricing type and an ultimate completion date of March 3, 2025. AmerisourceBergen Drug...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,293.58 firm fixed-price contract is for the delivery of Quillivant XR 25 mg/5 ml suspension, a medication for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). The contract has an ultimate completion date of November 27, 2024 and was awarded on November 26, 2024. It is not designated as a set-aside...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of Quillivant XR Oral Suspension, a medication used to treat Attention Deficit Hyperactivity Disorder (ADHD). The contract has a ceiling value of $7,630.42 and is a firm fixed-price contract with an ultimate completion date of April 16, 2025. This contract is not a set-aside and was...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,121.73 firm-fixed-price delivery order is for the supply of Quillivant XR 25 mg/5 ml suspension, a medication used to treat Attention Deficit Hyperactivity Disorder (ADHD). The contract, which has an ultimate completion date of October 30, 2024, is a part of a larger Indefinite Delivery Contract (IDC) between...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $2,553.87, is for the supply of Quillivant XR 25 mg/5 ml suspension, a medication used to treat attention-deficit/hyperactivity disorder (ADHD). The contract is a firm-fixed price delivery order, with an ultimate completion date of April 22, 2025. This contract is not set aside for any specific business category....
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has a ceiling value of $2,343.11 and is for the supply of Quillivant XR 25 mg/5 ml suspension, a medication used to treat attention-deficit/hyperactivity disorder (ADHD). The contract is a firm fixed-price delivery order with a period of performance through February 18, 2025. It is not designated as a set-aside...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award, valued at $2,628.40, is for the delivery of Quillivant XR 25 mg/5 ml suspension, a medication used to treat Attention Deficit Hyperactivity Disorder (ADHD). The contract is a Firm Fixed Price Delivery Order with a completion date of February 5, 2025. Amerisourcebergen holds a significant Indefinite Delivery...